phine, oxymorphone, and oxycodone. We excluded methadone, because many patients use this agent to manage addiction instead of pain.
From an initial sample of 93 282 214 prescriptions, we excluded 719 080 (0.8%) for which the quantity supplied or dosage was missing. After converting each prescription to oral morphine equivalents (MEQs) (3), we calculated the total annual MEQs for each patient in our sample. We then calculated the total MEQs used by the entire sample, as well as the share of this total used by patients in each percentile group (for example, the top percentile in terms of MEQ) on an annual basis. After we excluded patients with a history of cancer, defined as those who had any claim with a relevant diagnosis code (n = 969 163) (4), our final sample consisted of 19 530 587 patients and 31 156 099 person-year observations. Patients were followed for every calendar year in which they maintained continuous enrollment (mean follow-up, 4 years [interquartile range, 2 to 6 years]).
In 2013, the top 5% of opioids users (that is, the 95th percentile) accounted for 59% of all MEQs and the top 10% accounted for 76% ( Figure 1 ). By contrast, in 2001, the top 5% accounted for 55% of all MEQs and the top 10% accounted for 69%, suggesting that opioid use became concentrated among fewer users over the study period (P < 0.001 for both differences) ( Figure 2) . The top 10% of opioid users were older (average age, 47 vs. 41 years) and more likely to be male (46% vs. 44%; P < 0.001 for both differences) than other users. Overall, 35% of patients among the top 10% remained in this group throughout their duration in the sample. Overall, 0.4% of all patients were prescribed an average daily dose of more than 90 MEQ, the limit recommended by the Centers for Disease Control and Prevention.
Discussion: In a sample of privately insured U.S. adults without cancer aged 18 to 64 years, the top 10% of patients accounted for most opioid use. Extrapolating to the entire U.S. population of prescription opioid users-approximately 100 million (5)-suggests that 10 million persons account for most U.S. opioid use. Further research efforts aimed at characterizing this population, analyzing the incidence of opioidrelated adverse events, and identifying approaches to reduce opioid use could be most effective in reducing total population-level use, especially because adverse events are most common at the highest MEQs (1). In addition, understanding the distribution of use in other populations not stud- ied here (for example, Medicare recipients) and of opioid prescribing across physicians is important.
Study limitations include the inability to specifically determine whether opioid use was inappropriate or to differentiate between scheduled versus as-needed dosing and restricting analysis to certain opioids.
